Health ❯ Healthcare ❯ Clinical Trials

Immunotherapy

Pembrolizumab Combination Therapy Atezolizumab CAR T-cell Therapy Autoimmune Diseases Nivolumab Immune Checkpoint Inhibitors EV-303 Oncolytic Viruses Fecal Microbiota Transplants Biopsy Techniques Personalized Cancer Vaccines QUILT-3.032 Trial PD-L1 Testing Leukaemia Treatments GLSI-100 TG4050 Viral Immunotherapy Durvalumab CAR-T-cell Therapy

Transgene Completes Phase 2 Randomization for Personalized Cancer Vaccine TG4050

The program now advances toward immune-response readouts in 2026 and a disease-free survival result by the end of Q1 2028.

Laser-Guided Tumor Ablation Plus Pembrolizumab More Than Doubles Survival in Recurrent Astrocytoma Trial

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

Trials Show Fecal Transplants Enhance Cancer Immunotherapy, Including Longer PFS in Randomized Kidney Study

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

NICE Backs Obe-cel for Adults With Aggressive Leukaemia as NHS Fast-Tracks Rollout

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

Serial Biopsies Reveal Responses Missed by MRI in Glioblastoma CAN-3110 Trial

Perioperative Nivolumab Preserves Quality of Life in Resectable NSCLC, WCLC 2025 Data Show

NICE Approves Keytruda Combo for Advanced Endometrial Cancer on NHS

Meta-Analysis Shows 43% Overall Response for Fecal Transplants Combined with Cancer Immunotherapy

Modified Herpes Virus Plus Nivolumab Induces Tumor Regression in Advanced Melanoma